CSL Limited (ASX:CSL)
Australia · Delayed Price · Currency is AUD 207.82
+2.01 (0.98%)
Sep 12, 2025, 4:12 PM AEST
CSL Limited Employees
CSL Limited had 29,904 employees as of June 30, 2025. The number of employees decreased by 2,794 or -8.54% compared to the previous year.
Employees
29,904
Change (1Y)
-2,794
Growth (1Y)
-8.54%
Revenue / Employee
793.56K AUD
Profits / Employee
153.12K AUD
Market Cap
100.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29,904 | -2,794 | -8.54% |
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | 25,000 | -2,000 | -7.41% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pro Medicus | 132 |
| Cochlear | 5,500 |
| Sonic Healthcare | 42,000 |
| Ramsay Health Care | 90,000 |
| Ansell | 15,000 |
| Telix Pharmaceuticals | 234 |
| Mesoblast | 81 |
| Neuren Pharmaceuticals | 8 |
CSL Limited News
- 24 days ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 24 days ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 24 days ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 24 days ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 3 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire
- 4 months ago - England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy - PRNewsWire
- 4 months ago - CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - PRNewsWire